Treatment of recurrent hepatocellular carcinoma after liver transplantation

Hye Ryun Kim, Seong Ha Cheon, Sun Young Rha, Soohyeon Lee, Kwang Hyub Han, Chae Yoon Chon, Jong Doo Lee, Jin Sil Sung, Hyun Cheol Chung

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: Liver transplantation (LT) is a curative treatment for localized hepatocellular carcinoma (HCC), but the recurrence rate after LT is about 10-20%, with a dismal prognosis. Little data exist as to the natural history, treatment outcome and optimal treatment of recurrent HCC after LT. We reviewed various treatment modalities given to patients with recurrent HCC after LT. Methods: Among 132 patients who underwent LT for localized HCC, we retrospectively reviewed medical records of 39 of the 132 patients who developed recurrent HCC after LT. We analyzed the clinical outcome of various treatment modalities and treatment-related adverse events. Results: A total of 39 (29%) of the original 132 patients had recurrent HCC, most recurrences (82%) having occurred within 1year after LT and involved extrahepatic lesions. Only seven patients had recurrent disease limited to the liver. The median overall survival from the initial treatment of all relapsed patients was 6.9 months. There were various initial treatment modalities, namely palliative systemic chemotherapy, trans-catheter arterial chemo-embolization/infusion (TACE/I), radiation therapy (RT), surgical resection and no treatment. The median overall survival was 9.5 months for first-line chemotherapy, including those who had prior local therapy, 6.3 months TACE/I and 6.9 months for RT. Conclusion: Various clinical approaches have been used to treat patients with recurrent HCC after LT in a clinical setting. More effective strategies and clinical guidelines for recurrent HCC following LT must be established.

Original languageEnglish
Pages (from-to)258-269
Number of pages12
JournalAsia-Pacific Journal of Clinical Oncology
Volume7
Issue number3
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Therapeutics
Radiotherapy
Catheters
Recurrence
Drug Therapy
Survival
Natural History
Medical Records
Guidelines
Liver

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hye Ryun ; Cheon, Seong Ha ; Rha, Sun Young ; Lee, Soohyeon ; Han, Kwang Hyub ; Chon, Chae Yoon ; Lee, Jong Doo ; Sung, Jin Sil ; Chung, Hyun Cheol. / Treatment of recurrent hepatocellular carcinoma after liver transplantation. In: Asia-Pacific Journal of Clinical Oncology. 2011 ; Vol. 7, No. 3. pp. 258-269.
@article{fd2b7e28e5af488dba6aa6410492586f,
title = "Treatment of recurrent hepatocellular carcinoma after liver transplantation",
abstract = "Aim: Liver transplantation (LT) is a curative treatment for localized hepatocellular carcinoma (HCC), but the recurrence rate after LT is about 10-20{\%}, with a dismal prognosis. Little data exist as to the natural history, treatment outcome and optimal treatment of recurrent HCC after LT. We reviewed various treatment modalities given to patients with recurrent HCC after LT. Methods: Among 132 patients who underwent LT for localized HCC, we retrospectively reviewed medical records of 39 of the 132 patients who developed recurrent HCC after LT. We analyzed the clinical outcome of various treatment modalities and treatment-related adverse events. Results: A total of 39 (29{\%}) of the original 132 patients had recurrent HCC, most recurrences (82{\%}) having occurred within 1year after LT and involved extrahepatic lesions. Only seven patients had recurrent disease limited to the liver. The median overall survival from the initial treatment of all relapsed patients was 6.9 months. There were various initial treatment modalities, namely palliative systemic chemotherapy, trans-catheter arterial chemo-embolization/infusion (TACE/I), radiation therapy (RT), surgical resection and no treatment. The median overall survival was 9.5 months for first-line chemotherapy, including those who had prior local therapy, 6.3 months TACE/I and 6.9 months for RT. Conclusion: Various clinical approaches have been used to treat patients with recurrent HCC after LT in a clinical setting. More effective strategies and clinical guidelines for recurrent HCC following LT must be established.",
author = "Kim, {Hye Ryun} and Cheon, {Seong Ha} and Rha, {Sun Young} and Soohyeon Lee and Han, {Kwang Hyub} and Chon, {Chae Yoon} and Lee, {Jong Doo} and Sung, {Jin Sil} and Chung, {Hyun Cheol}",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1743-7563.2011.01425.x",
language = "English",
volume = "7",
pages = "258--269",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "3",

}

Treatment of recurrent hepatocellular carcinoma after liver transplantation. / Kim, Hye Ryun; Cheon, Seong Ha; Rha, Sun Young; Lee, Soohyeon; Han, Kwang Hyub; Chon, Chae Yoon; Lee, Jong Doo; Sung, Jin Sil; Chung, Hyun Cheol.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 7, No. 3, 01.09.2011, p. 258-269.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of recurrent hepatocellular carcinoma after liver transplantation

AU - Kim, Hye Ryun

AU - Cheon, Seong Ha

AU - Rha, Sun Young

AU - Lee, Soohyeon

AU - Han, Kwang Hyub

AU - Chon, Chae Yoon

AU - Lee, Jong Doo

AU - Sung, Jin Sil

AU - Chung, Hyun Cheol

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Aim: Liver transplantation (LT) is a curative treatment for localized hepatocellular carcinoma (HCC), but the recurrence rate after LT is about 10-20%, with a dismal prognosis. Little data exist as to the natural history, treatment outcome and optimal treatment of recurrent HCC after LT. We reviewed various treatment modalities given to patients with recurrent HCC after LT. Methods: Among 132 patients who underwent LT for localized HCC, we retrospectively reviewed medical records of 39 of the 132 patients who developed recurrent HCC after LT. We analyzed the clinical outcome of various treatment modalities and treatment-related adverse events. Results: A total of 39 (29%) of the original 132 patients had recurrent HCC, most recurrences (82%) having occurred within 1year after LT and involved extrahepatic lesions. Only seven patients had recurrent disease limited to the liver. The median overall survival from the initial treatment of all relapsed patients was 6.9 months. There were various initial treatment modalities, namely palliative systemic chemotherapy, trans-catheter arterial chemo-embolization/infusion (TACE/I), radiation therapy (RT), surgical resection and no treatment. The median overall survival was 9.5 months for first-line chemotherapy, including those who had prior local therapy, 6.3 months TACE/I and 6.9 months for RT. Conclusion: Various clinical approaches have been used to treat patients with recurrent HCC after LT in a clinical setting. More effective strategies and clinical guidelines for recurrent HCC following LT must be established.

AB - Aim: Liver transplantation (LT) is a curative treatment for localized hepatocellular carcinoma (HCC), but the recurrence rate after LT is about 10-20%, with a dismal prognosis. Little data exist as to the natural history, treatment outcome and optimal treatment of recurrent HCC after LT. We reviewed various treatment modalities given to patients with recurrent HCC after LT. Methods: Among 132 patients who underwent LT for localized HCC, we retrospectively reviewed medical records of 39 of the 132 patients who developed recurrent HCC after LT. We analyzed the clinical outcome of various treatment modalities and treatment-related adverse events. Results: A total of 39 (29%) of the original 132 patients had recurrent HCC, most recurrences (82%) having occurred within 1year after LT and involved extrahepatic lesions. Only seven patients had recurrent disease limited to the liver. The median overall survival from the initial treatment of all relapsed patients was 6.9 months. There were various initial treatment modalities, namely palliative systemic chemotherapy, trans-catheter arterial chemo-embolization/infusion (TACE/I), radiation therapy (RT), surgical resection and no treatment. The median overall survival was 9.5 months for first-line chemotherapy, including those who had prior local therapy, 6.3 months TACE/I and 6.9 months for RT. Conclusion: Various clinical approaches have been used to treat patients with recurrent HCC after LT in a clinical setting. More effective strategies and clinical guidelines for recurrent HCC following LT must be established.

UR - http://www.scopus.com/inward/record.url?scp=80052235364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052235364&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2011.01425.x

DO - 10.1111/j.1743-7563.2011.01425.x

M3 - Article

C2 - 21884437

AN - SCOPUS:80052235364

VL - 7

SP - 258

EP - 269

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 3

ER -